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Regenerative proliferation capacity and poor differentiation are histological features usually
linked to poor prognosis in head and neck squamous cell carcinoma (hnSCC). However, the
pathways that regulate them remain ill-characterized. Here, we show that those traits can be
triggered by the RHO GTPase activator VAV2 in keratinocytes present in the skin and oral
mucosa. VAV2 is also required to maintain those traits in hnSCC patient-derived cells. This
function, which is both catalysis- and RHO GTPase-dependent, is mediated by c-Myc- and
YAP/TAZ-dependent transcriptomal programs associated with regenerative proliferation and
cell undifferentiation, respectively. High levels of VAV2 transcripts and VAV2-regulated gene
signatures are both associated with poor hnSCC patient prognosis. These results unveil a
druggable pathway linked to the malignancy of speci!c SCC subtypes.
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Cutaneous (cSCC) and hnSCCs develop from the strati!edepithelia of the skin and the mucosal lining of the upperaerodigestive tract, respectively. These tumors represent
nowadays a clinical challenge due to increasing incidence
worldwide, aggressiveness, poor prognosis, and limited ef!cacy of
available therapeutic tools. Risk factors for these tumors include
ultraviolet ray exposure (in the case of cSCCs), alcohol intake,
smoking, and human papillomavirus (HPV) infection (in the case
of hnSCCs)1,2. These SCCs share histological features similar to
those found in the most undifferentiated basal layers of healthy
epithelia. However, they can display variable numbers of cells that
had undergone both terminal differentiation and growth arrest.
This variability is clinically relevant, since tumors with less dif-
ferentiated features usually exhibit worse disease outcomes1.
These data suggest that pathobiological programs that regulate
regenerative proliferation plus delayed differentiation drive both
the tumorigenesis and malignancy of this type of tumors. In line
with this, it has been proposed that therapies that elicit the
terminal differentiation of cancer cells could be of high utility in
hnSCC1. To date, however, we still have a poor understanding of
the molecular and signaling programs that regulate these malig-
nant traits. Recent work in this area has revealed that nuclear
factors such as AP1 and E2F family members, c-MYC, the YAP/
TAZ complex, TP63, and ACTL6A can trigger those processes3–8.
These proteins seem to act in a concerted manner, as exempli!ed
by the presence of composite cis-gene DNA regulatory elements
for many of them in the target genes5,6.
Recent tumor molecular taxonomy studies have revealed that
the activation of RHO GTPase-regulated biological processes is a
common signaling feature for most SCCs9. Consistent with this,
the gene encoding the RAC1 GTPase has been found mutated at
low frequency in cSCC and hnSCC10. High levels of active RAC1
are also found in a large variety of hnSCCs11,12. This activation
has been linked to the development of chemo- and radio-
resistance in patients12. It is not presently known whether the role
of this GTPase is associated with the regulation of its canonical
cytoskeletal-related functions13,14 and/or to regenerative pro-
liferation in those tumors. However, the observation that the
elimination of RAC1 activity reduces the clonogenicity of hnSCC
cell lines suggest that this GTPase can be involved in the reg-
ulation of the latter pathobiological program12,15. Unfortunately,
efforts at blocking RAC1 signaling pathways in tumors have failed
so far due to the intrinsic undruggability of RHO GTPases and
the unwanted side-effects of inhibitors for downstream elements
such as the Pak family of serine/threonine kinases10.
An alternative way to targeting these pathways is by inhibiting
the catalytic activity of RHO guanosine nucleotide exchange
factors (GEFs), the enzymes that promote the stimulation step of
RHO proteins in cells10. Supporting this idea, genetic analyses
have shown that either the single (Tiam1) or the compound
(Vav2 plus Vav3) depletion of some RHO GEFs can abate
carcinogen-induced skin tumor formation while maintaining skin
homeostasis in mice16,17. Catalytically hypomorphic Vav2 knock-
in mice also show impaired skin tumorigenesis using the above
experimental protocols18. Yet, very little is known regarding the
speci!c RHO GEFs that become deregulated in human tumors
and the pathways engaged by them10. Addressing these issues is
not an easy task, given that the RHO GEF family is composed of
more than 70 members in humans10.
In this work, we report that the RHO GEF VAV2 is fre-
quently overexpressed in both cSCC and hnSCC cases. We also
demonstrate that this GEF is associated with the engagement of
a pathobiological program linked to stem cell-like regenerative
proliferation in epithelial cells located in the skin and head and
neck areas. Conversely, we show that high levels of endogenous
VAV2 are required to maintain the tumorigenic activity of
hnSCC patient-derived cells. Along those lines, we have found
that the expression levels of the VAV2 mRNA and VAV2-
regulated gene signatures correlate with disease outcome in
hnSCC patients.
Results
VAV2 mRNA levels correlate with poor prognosis in hnSCC.
Previous data suggested that, out of the 70 RHO exchange factors
present in humans, the GEF VAV2 could be potentially involved
in both hnSCC and cSCC tumorigenesis. This GEF belongs to the
VAV family, a group of GEFs (VAV1, VAV2, VAV3) whose
exchange activity is regulated by direct tyrosine phosphorylation
events19,20. In favor of the connection of VAV2 with this type of
tumors, work with human hnSCC cell lines has revealed that this
GEF is frequently tyrosine phosphorylated and involved in the
stimulation of RAC1 downstream of the epidermal growth factor
receptor (EGFR) in a signi!cant number of the interrogated cell
lines11. Furthermore, the use of catalytically de!cient Vav2
knock-in mice has demonstrated that the inhibition of the
enzymatic activity of Vav2 impairs both the papilloma and cSCC
formation that are typically induced upon the topic administra-
tion of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA)
either alone or in combination with the tumor promoter 12-O-
tetradecanoylphorbol-13-acetate (TPA)11. To investigate this
possibility, we !rst analyzed using in silico techniques the
expression of VAV2 transcripts in cSCC and hnSCC patients. To
this end, we interrogated four independent gene expression
datasets from either cSCC (GEO GSE13355 and GSE45216) or
hnSCC (GEO GSE30784 and TCGA; for further information, see
both Supplementary Table 1 and “Methods” section) patients. In
the case of hnSCC, the TCGA collection harbored samples with
(21% of cases) and without information on HPV status. The GEO
GSE30784 lacks information on HPV status, although the per-
centage of HPV– samples has been estimated to be in the 75%
range21 (Supplementary Table 1). These datasets were chosen
because: (i) They contained expression data from both healthy
and tumor samples. (ii) They included a minimum of 100 sam-
ples (to facilitate the generation of statistically robust data). (iii)
They included samples with clinical information (e.g., dysplasia,
stage of tumor progression, etc.). Using this approach, we found
that the VAV2mRNA is consistently upregulated in human cSCC
(Fig. 1a, left panel) and hnSCC (Fig. 1a, second and third panels
from left) when compared to healthy tissue samples. In the case of
hnSCCs, higher expression is detected in HPV! than in HPV+
tumors (Fig. 1a, third panel from left). Moderate overexpression
levels of VAV2 transcripts are also found in precancerous con-
ditions such as cutaneous actinic keratosis (Fig. 1a, left panel) and
oral epidermal dysplasia (Fig. 1a, second panel from left). How-
ever, the elevation in VAV2 transcripts is much less noticeable in
skin samples from psoriasis patients (Fig. 1a, left panel). The
mouse Vav2 mRNA also shows a progressive increase in
expression along the progression of cSCCs (Fig. 1a, right panel)
when interrogated in the available GSE21264 gene expression
microarray dataset (Supplementary Table 1), indicating that the
deregulation of this gene is conserved in SCCs from different
species. We did not observe any statistically signi!cant elevation
in VAV1, a mRNA encoding a VAV family member that shows
a hematopoietic-speci!c pattern of expression19,20,22, in any of
those pre- and neoplastic stages (Supplementary Fig. 1a). By
contrast, the VAV1 mRNA does show a small, although statisti-
cally signi!cant enrichment in the case of samples from psoriatic
patients (Supplementary Fig. 1a, left panel). These data suggest
that the changes seen in VAV2 mRNA levels are probably
intrinsic to tumor cells rather than an indirect consequence of the
presence of varying amounts of in!ltrating hematopoietic cells in
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the interrogated samples. Taken together, these observations
indicate that the VAV2 mRNA is frequently overexpressed in
both cSCCs and HPV– hnSCCs. This is SCC type-speci!c,
because we could not !nd any statistically signi!cant elevation
of VAV2 transcripts in SCCs from the lung and cervix (Supple-
mentary Fig. 1b, Supplementary Table 1).
We next investigated whether the abundance of VAV2
transcripts correlated with disease outcome. We focused these
analyses on hnSCC, given that no data are available on cSCC due
to the typically high survival rates exhibited by these patients23.
To this end, we carried out in silico analyses using three
independent gene expression datasets (TCGA, GEO GSE41613,
and GEO GSE42743, Supplementary Table 1). These datasets
were chosen because: (i) They contained information of at least
90 independent clinical cases. (ii) They have information on long-
term survival, HPV status, and other clinical criteria of patients.
These analyses indicated that the levels of the VAV2 mRNA
directly correlated with poor HPV! patient prognosis in these
three independent datasets (Figs. 1b and S1c). The strati!cation
power conferred by the VAV2 mRNA levels is in fact better in
terms of statistical signi!cance than that obtained when using the
expression level of the transcripts for the EGFR (Fig. 1b, bottom
panels), a tyrosine kinase receptor encoded by a gene frequently
ampli!ed in hnSCC (Supplementary Fig. 1d)2. It is also better
than that conferred by the levels of ACTL6A (Supplementary
Fig. 1e, left panel), a transcript encoding a hnSCC protumorigenic
factor that is upregulated at similar levels between HPV+ and
HPV– tumors (Supplementary Fig. 1f)8. Unlike the case of
ACTL6A (Supplementary Fig. 1e, two left panels), the diagnostic
power of the VAV2 and EGFR mRNA levels is lost when using
patient cohorts that have not been classi!ed according to HPV
status (Supplementary Fig. 1e, third and fourth panels from left).
Further multivariable analyses indicated that the VAV2 mRNA
levels do not show any statistically signi!cant association with
tumor stage, smoking status, or therapeutic response.
The upregulation of the VAV2 mRNA is not associated with
gene ampli!cation events (Supplementary Fig. 1d). It is also
speci!c for the VAV2 locus, because the two genes that "ank the
VAV2 gene (SARDH, BRD3) do not show any consistent
variation in expression in the human and mouse tumor datasets
interrogated in this study (Supplementary Fig. 1g). The analysis of
Pan-Cancer data also indicates that VAV2 is seldom mutated in
hnSCC cases24–26 (Supplementary Fig. 1d). However, it is worth
noting that during the elaboration of this work this locus was
found to be mutated at higher rates in hereditary cases of oral
SCC27. The recurrent gain-of-function mutation found in those
tumors (Val872 to Ile) targets a residue located in the most C-
terminal VAV2 SH3 (C-SH3) domain, a region previously shown
to be involved in the formation of the intramolecular interactions
that maintain the inhibitory structure of all Vav family members
when they are not tyrosine-phosphorylated28. Taken together,
these results indicate that VAV2 is commonly upregulated in
speci!c SCC subtypes. They also indicate that this upregulation
correlates with poor prognosis in the case of HPV– hnSCC
patients.
Wild-type VAV2 is overexpressed in hnSCCs. We next per-
formed immunoprecipitation analyses to monitor the levels of
VAV2 in cellular extracts from 83 HPV– hnSCC patient samples.
As control, we included lysates from healthy tissues that were in
the vicinity of the tumors extracted from the same patients.
Consistent with the foregoing in silico mRNA expression ana-
lyses, we found that VAV2 is detected at much higher levels in the
tumor than in the healthy tissue samples (Fig. 2a, b). Further
Western blot analyses revealed that the endogenous VAV2 is also
tyrosine phosphorylated in most of those samples (Fig. 2a, c). In
addition to the estimation of the protein content present in the
tissue extracts using the Bradford’s method, the presence of
similar amounts of total protein in the tissue lysates used in these
immunoprecipitation analyses was rechecked by running aliquots
of them in SDS-PAGE gels and, after transferring to nitrocellulose
!lters, staining the separated proteins with Ponceau S solution
(Fig. 2a). We also found using standard immunohistochemical
techniques that 41.8% and 14.7% out of a total of 232 inde-
pendent cases (96.55% of them with a HPV– status) of hnSCC
samples that were surveyed display medium to high levels of
VAV2 immunoreactivity, respectively (Fig. 2d). This expression
is concentrated in the cancer cells rather than in the sur-
rounding stromal components (Fig. 2d), further demonstrating
that the upregulation of VAV2 is a cancer cell-intrinsic phe-
nomenon. VAV2 staining does not signi!cantly correlate with
the differentiation grade in our patient cohort (P < 0.86).
Nevertheless, it is worth mentioning that VAV2 staining was
consistently absent in all terminal differentiation areas of the
samples (e.g., keratin pearls) even in the case of VAV2-positive
tumors (Fig. 2e, asterisk).
The above immunohistochemical studies also revealed that





















































































































Fig. 1 VAV2 mRNA levels correlate with poor prognosis in HPV– hnSCC.
a Expression of VAV2 mRNA in indicated samples (bottom) and gene
expression datasets (top). *P= 0.029 (dysplasia versus healthy, hnSCC),
0.047 (HPV! versus HPV+ hnSCC); **P= 0.005 (psoriasis versus healthy,
cSCC); ***P < 0.0001 (all other analyses) using ANOVA and Tukey’s HSD
tests (from left to right, n= 220, 229, 155, and 273 patient samples,
respectively). When data were generated using two datasets at the same
time, we used frozen robust multiarray analyses (fRMA) to avoid batch
effects as indicated in Methods. Data represent the mean ± SEM. b Survival
of HPV! hnSCC patients according to the abundance of VAV2 and EGFR
mRNAs in tumors in indicated datasets (top). The Mantel–Cox test P value
is indicated for each transcript. Source data for this !gure are provided as a
Source Data !le.
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layers of the normal oral epithelium obtained from the same
patients (Fig. 2f, left panel). However, we found that the VAV2
immunoreactivity expands to suprabasal cell layers when
analyzed in samples exhibiting histological signs of dysplasia
(Fig. 2f, right panel). The levels of immunoreactivity found in
the foregoing cases were lower than those detected in tumors
(Fig. 2d, e). The preferential expression of the VAV2 mRNA in
keratinocyte precursors and its downmodulation in more mature
derivatives is also observed in the skin when using gene
expression data from organotypic cultures that recapitulate this






























































































































































































Fig. 2 VAV2 protein is overexpressed in hnSCC. a Levels of total (VAV2) and tyrosine-phosphorylated (p-VAV2) VAV2 in healthy (H) and tumor (T)
tissues from hnSCC patients (n= 83). The band corresponding to the antibody used for the immunoprecipitation step is indicated (IgG). Amount of total
protein content in the extracts used for the immunoprecipitation was tested in parallel !lters using Ponceau staining (bottom panels). KDa, kilodalton.
b VAV2 abundance according to data from a. ***P < 0.0001 (two-tailed Mann–Whitney test, n= 83 patient samples). a.u., arbitrary units. c VAV2 tyrosine
phosphorylation levels according to data obtained in a. *P= 0.011 (two-tailed Mann–Whitney test, n= 83 patient samples). Please, note that the total
levels of tyrosine phosphorylation of VAV2 in these analyses are probably underestimated given the long experimental procedure associated with tumor
collection and subsequent lysis. d Example of tumor sections showing the indicated VAV2 immunoreactivity levels (IRL, top). The percentages of tumor
samples (% out of a total of 232 tumors analyzed) showing the indicated VAV2 immunoreactivity levels are shown at the bottom. n= 232 tumor samples.
Scale bar, 200 !m. e Representative image showing the lack of VAV2 immunoreactivity in terminally differentiated areas (asterisk) of VAV2-positive
tumors. Scale bar, 100 !m. f Representative images of the immunohistochemical staining of VAV2 in healthy (left) and dysplastic (right) samples from
human oral epithelium. Sections were counterstained with hematoxylin. n= 232 tumor samples. Scale bar, 100 !m. g Expression levels of the indicated
transcripts according to the differentiation status of keratinocytes. Data were obtained from the GEO GSE52651 dataset (see “Methods”). IVL involucrin
(an mRNA expressed from the early stages of keratinocyte terminal differentiation); LOR loricrin (a transcript encoding a major protein component of the
corni!ed cell envelope that is found in terminally differentiated epidermal cells). In b and c, data represent the mean ± SEM. Source data for this !gure are
provided as a Source Data !le.
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differentiation process (Fig. 2g). By contrast, differentiation-
associated transcripts show the expected upregulation as these cell
precursors progressively give rise to a more mature progeny
(Fig. 2g). Taken together, these results further indicate that the
levels of VAV2 become highly elevated in a signi!cant number of
hnSCC cases when compared to both normal and dysplastic
tissue conditions.
VAV2 promotes a protumorigenic niche in the mouse epi-
dermis. To investigate the effect of upregulated VAV2 signaling
in primary epithelial cells, we !rst made use of a previously
described Vav2Onc/Onc gain-of-function knock-in strain that
expresses a mutant version of the protein (!1-186, referred to
hereafter as Vav2Onc). This protein exhibits constitutive GEF
activity due to the removal of the N-terminal inhibitory regions
that, together with the C-SH3, maintain the inactive state of Vav
family proteins in the absence of tyrosine phosphorylation28,29.
Due to this, the activity of this active version must re"ect
the output of Vav2WT under optimal tyrosine phosphorylation
conditions according to the current regulatory model for Vav family
proteins19,20,30. Importantly, Vav2Onc is expressed from the endo-
genous locus and, therefore, exhibits the same pattern and levels
of expression that the endogenous wild-type (WT) counterpart29.
The analysis of these mice indicates the presence of extensive
hyperplasia in the epidermal layers of the skin, palate, and tongue
(Fig. 3a, b). This phenotype is associated with an increase in cell
layers composed of both immature and highly proliferative (keratin
5 and 6 positive) keratinocyte precursors (Fig. 3c). Corneum strata
are observed in all cases (Fig. 3a, c), indicating that Vav2Onc delays
but does not abate the terminal differentiation of keratinocytes.
In the case of the skin, we also observed frequent cases of dermal
dysplasia (Fig. 3a, top panels).
We did not !nd tumor development in the skin or head
and neck areas of Vav2Onc/Onc mice even after long periods
of time (12 months of age). However, we did observe that
those mice develop skin tumors with faster kinetics (Fig. 3d),
higher multiplicity (Fig. 3e), and of larger size (Fig. 3f) than
controls upon being subjected to a single topic administration
of DMBA at newborn stages. The malignant progression of
these tumors is also accelerated, as inferred from the increased
percentages of cSCCs found in Vav2Onc/Onc mice (Fig. 3g and
Supplementary Fig. 2). These results indicate that upregulated
Vav2 signaling creates a preneoplastic niche that favors full
epidermal transformation when combined with additional
genetic lesions.
The effect of Vav2 in epidermis is keratinocyte autonomous.
Since the hyperplasia can develop as a consequence of both
intrinsic and extrinsic factors to epithelial cells, we next investi-
gated the direct effect of upregulated Vav2 signaling in primary
mouse and human keratinocytes. To this end, we compared the
ability of keratinocytes obtained from the skin of newborn
WT and Vav2Onc/Onc mice to form epidermis-like structures
in organotypic 3D cultures (Fig. 4a). Similar to the results
obtained in mice, we found that the primary keratinocytes from
newborn Vav2Onc/Onc mice develop a thicker and more pro-
liferative epidermis than WT cells (Fig. 4a, b and Supplementary
Fig. 3a). To assess the level of phylogenetic conservation of this
phenotype, we next performed similar organotypic experiments
using immortalized human keratinocytes ectopically expressing
Vav2Onc. These cells also form thicker and more proliferative
layers than controls (Fig. 4c, d and Supplementary Fig. 3a, b).
As in the case of the mouse primary keratinocytes, the epidermis
formed by human keratinocytes ectopically expressing Vav2Onc is
characterized by the expansion of layers of highly undifferentiated
keratinocytes that still keep the ability to terminally differentiate
when reaching the outermost layers of the epithelium (Fig. 4c,
bottom panels). This phenotype is lost when a catalytically-dead
version of Vav2Onc (E200A mutant) is ectopically expressed in
human keratinocytes (Supplementary Fig. 3b and Fig. 4c, d),
indicating that Vav2 triggers the epithelial hyperplasia using a
catalysis-dependent mechanism.
To identify the downstream Rho GTPases involved in this
process, we performed G-ELISA assays to monitor the GTP
loaded (active) status of the endogenous Rac1, RhoA, and Cdc42
in the mouse and human keratinocytes utilized above. As positive
controls, we used human keratinocyte derivatives stably expres-
sing mutant versions of Rac1 (F28L mutant), RhoA (F30L
mutant), and Cdc42 (F28L mutant) (Supplementary Fig. 3c).
These mutant proteins show constitutive activity due to high
intrinsic rates of GDP/GTP exchange in the absence of upstream
stimulation31. We observed that both the endogenously (Fig. 4e,
left panel) and the ectopically expressed (Fig. 4e, right panel)
Vav2Onc proteins trigger the stimulation of Rac1 and RhoA in
mouse and human keratinocytes, respectively. However, we could
not !nd any statistically signi!cant elevation of the GTP levels of
endogenous Ccd42 (Fig. 4e, right panel). As control, the cell lines
expressing the GTPase mutant proteins show high GTP levels of
activation of the expected Rho protein (Fig. 4e, right panel). In
agreement with this, we observed that human keratinocytes
expressing Rac1F28L and, to a lesser extent the other constitutively
activated Rho GTPases elicit a hyperplasic response when tested
in 3D cultures (Fig. 4f, g). This response is more clearly seen in
keratinocytes coexpressing Rac1F28L and RhoAF30L (Fig. 4f, g and
Supplementary Fig. 3d). As in the case of Vav2Onc-expressing
cells (Fig. 4a, c), this phenotype is associated with increased
numbers of proliferative and undifferentiated strata of keratino-
cytes (Fig. 4h). In line with the implication of Rac1 and RhoA in
this process, we found that the epithelial hyperplasia elicited by
ectopically expressed Vav2Onc can be blocked by inhibitors of
well-known proximal downstream elements of the Rac1 (Pak
kinases) and RhoA (Rock kinases) pathways (Supplementary
Fig. 3e, f)10. Collectively, these results indicate that the biological
effects triggered by Vav2Onc in the epidermis are keratinocyte
autonomous and catalysis-dependent.
Vav2 controls a protumorigenic and stem cell-like program in
keratinocytes. We next performed microarray analyses using
samples from the epidermis of WT and Vav2Onc/Onc mice to get
information on the biological programs associated with upre-
gulated Vav2 signaling in the epidermis. We found a total of
2,153 probe sets (1,881 genes) whose expression is differentially
deregulated in Vav2Onc/Onc mice (Supplementary Data 1).
Interestingly, !37.4% and 40.5% of the up- and downregulated
subsets (referred to hereafter as “redundant transcriptome”)
display an opposite regulation to that found in the previously
described response of the skin of Vav2–/–;Vav3–/– mice to the
tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)17
(Supplementary Fig. 4, Supplementary Table 2). This suggests
that a signi!cant fraction of the transcriptome that is elicited by
TPA during the promotion phase of skin tumorigenesis can also
be triggered by Vav2Onc in a signaling autonomous manner.
Functional annotation analyses revealed that these gene
expression changes are consistent with the phenotype observed
in Vav2Onc/Onc mice, including the deregulation of genes asso-
ciated with proliferative and epidermal differentiation programs
(Fig. 5a). The use of Gene Set Enrichment analyses (GSEA)
con!rmed the foregoing programs and, in addition, further
underscored the impact of increased Vav2 signaling on
the overall differentiation program of keratinocytes. These
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effects included the downregulation and upregulation of gene
signatures characteristic of late epidermal differentiation- and
epidermal cell progenitor-associated programs (Fig. 5b, upper
panels), respectively. Perhaps more importantly, we found the
enrichment of gene signatures related to cSCC tumor initiating
cells and embryonic stem cells in the Vav2Onc-induced tran-
scriptome (Fig. 5b, bottom panels). No statistically signi!cant
overlaps are found with the transcriptomes of normal hair fol-
licle stem cells, indicating that Vav2Onc triggers an aberrant
dedifferentiation process more similar to general stem cells than
to those found in the most undifferentiated skin precursors. In
line with the induction of the combination of proliferative and
stem cell like-programs, we found that the epidermis of
Vav2Onc/Onc mice reacts to the topic administration of a single
dose of TPA with more rapid and wide proliferative responses
than the skin from control animals (Fig. 5c). We also observed
that the primary keratinocytes from newborn Vav2Onc/Onc mice
generate higher numbers of induced pluripotent stem (iPS) cell
colonies than the WT counterparts upon transfection with the
Yamanaka’s cocktail (Fig. 5d). These observations indicate
that the upregulation of Vav2 signaling leads to a stem cell-like
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Fig. 3 Upregulated VAV2 signaling creates a protumorigenic niche. a Histological sections of the epithelia from mice of the indicated genotypes. The
thickness of the epithelium is indicated with a bracket. Scale bar, 100 (back and ear skin) and 200 (palate and tongue) !m (n= 6 animals per genotype).
b Thickness of indicated epithelial linings according to the data gathered in a. ***P < 0.0001 (two-tailed Student’s t-test, n= 6 animals per genotype).
px pixel. c Expression of keratin 5 (K5; top, red color), keratin 6 (K6; bottom, red color), and keratin 10 (K10; both panels, green color) in the skin from the
back of animals of indicated genotypes. In all cases, the nuclei of cells were labeled with DAPI (blue color). Scale bar, 50 !m (n= 3). Penetrance (d) and
multiplicity (e) of tumors generated in mice of the indicated genotypes upon a single topic DMBA application at postnatal day 3. The differences between
genotypes were statistically signi!cant from week 12 onwards (P < 0.0001, two-tailed Student’s t-test). n= 24 and 31 WT and Vav2Onc/Onc mice,
respectively. f Size distribution of the tumors at the endpoint of the experiment shown in d. ***P < 0.0001 (two-tailed Student’s t-test, n as in d). g Tumor
type distribution at the endpoint of the experiment shown in d. P < 0.0001 (Chi-squared test, n= 15 and 72 WT and Vav2Onc/Onc tumors, respectively). In
b, e, and f, data represent the mean ± SEM. Source data for this !gure are provided as a Source Data !le.
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differentiation that probably contribute to the epidermal
hyperplasia seen in Vav2Onc/Onc mice.
In line with the protumorigenic status of the epidermis of
Vav2Onc/Onc mice, bioinformatics analyses revealed that the
Vav2Onc-associated transcriptome shares a large degree of
overlap with gene expression programs present in mouse
papilloma and cSCC (Fig. 5e, left panels), human cSCC (Fig. 5e,
middle panels), human hnSCCs (Fig. 5e, right panels), and
human oral epidermal dysplasia (Fig. 5e, right panels).
























































































































































































































Fig. 4 The effect of Vav2 in epidermis is keratinocyte autonomous. a Hematoxylin-eosin- (top) and Ki67- plus hematoxylin-stained (bottom) tissue
sections from organotypic cultures using neonatal keratinocytes of indicated genotypes. The thickness of the corneum and cellular epidermal strata is
indicated with red and blue brackets, respectively. Scale bar, 10 !m (n= 6 independent cultures). b Thickness of the indicated skin strata according to data
from a. ***P < 0.0001 (two-tailed Student’s t-test, n= 6 independent cultures). c Representative images of indicated organotypic cultures after staining
with hematoxylin-eosin (top panels) and antibodies to Ki67 (middle panels), involucrin (IVL, bottom, red color), and keratin 14 (K14, green color). Some of
the sections were subsequently counterstained with either hematoxylin (middle row of panels) or DAPI (bottom panels, blue color). Scale bar, 10 !m. n= 8
(Mock and Vav2Onc) and 5 (Vav2Onc+E200A). d Thickness of the indicated skin strata according to data obtained in c. *P= 0.029; ***P < 0.0001 (two-
tailed Student’s t-test, n as in panel c). e GTP-bound levels of Rac1, RhoA, and Cdc42 in indicated cells. *P= 0.013; **P= 0.002; ***P < 0.0001 (ANOVA
and Tukey’s HSD test, n= 3 independent experiments). f Histological sections of 3D cultures of human keratinocytes expressing indicated proteins. Scale
bar, 10 !m (n= 5 independent cultures). g Thickness of the indicated epidermal strata according to data from f. *P= 0.047 (Vav2Onc corneum stratum),
0.011 (Rac1F28L corneum stratum), 0.033 (Cdc42F28L corneum stratum); **P= 0.003 (Cdc42F28L cellular stratum); ***P < 0.0001 (all other tests)
(ANOVA and Dunnett’s multiple comparison test, n= 5 independent cultures). h Immunohistochemical staining of mock- and Rac1F28L+ RhoAF30L-
expressing human keratinocytes with antibodies to Ki67 (top panels), IVL (bottom, red color) and K14 (bottom, green color). Sections were counterstained
with either hematoxylin (top panels) or DAPI (bottom panels, blue color). Scale bar, 10 !m (n= 3). In b, d, e, and g, data represent the mean ± SEM. Source
data for this !gure are provided as a Source Data !le.
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characteristic of metastatic hnSCC patient-derived cells and
mouse cSCCs (Fig. 5f). Taken together, these results indicate
that the upregulation of Vav2 signaling is associated with the
generation of an undifferentiated, regenerative population of
epidermal precursors that bear many biological and transcrip-
tomal features with squamous epithelial tumors originated from
both the skin and head and neck areas.
Regulatory elements of the Vav2Onc transcriptome. We next
carried out further in silico analyses to obtain clues about the
distal transcriptional factors involved in the regulation of the
Vav2Onc-dependent gene expression program. We found that the
upregulated genes of this transcriptome are enriched in binding
sites for the AP1 family, c-Myc, E2F, Nfy, and TEAD (Fig. 6a, b).
By contrast, the downregulated genes seem to be under the reg-
ulation of a different subset of transcriptional factors such as Mitf,
Mef2, FoxO, and RXR" (Fig. 6a, b). Consistent with these data,
GSEAs demonstrated the presence of gene signatures previously
linked to those factors in the Vav2Onc-dependent transcriptome
(Supplementary Fig. 5a).
Given that upregulated genes are easier to tamper with
than downregulated ones in the context of both biological and
Normal/Papilloma/cSCC Normal/Psoriasis/AK/cSCC Normal/Dysplasia/hnSCC
Normal/Papilloma/cSCC Normal/Psoriasis/AK/cSCC Normal/Dysplasia/hnSCC
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therapeutic systems, we decided to focus our validation studies
on the transcriptional factors associated with the upregulated
gene subset of the Vav2Onc-dependent transcriptome. Using
immunohistochemical analyses, we con!rmed that c-Fos
(an AP1 family member), c-Myc, Cyclin D1 (used as a
surrogate for the activity of E2F family proteins), and YAP
are both upregulated and nuclear-localized in the epidermis of
Vav2Onc/Onc mice (Fig. 6c, two columns of panels on the left).
Similar results were obtained using immunohistochemical
experiments with epidermal sections from the organotypic
cultures generated by both mouse Vav2Onc/Onc (Fig. 6c, third
and fourth set of column panels from the left) and Vav2Onc-
expressing human (Fig. 6c, rest of panels) keratinocytes. We
also found higher levels of nuclear-localized c-Fos, c-Myc, and
YAP in the epidermis formed by keratinocytes ectopically
coexpressing the active versions of both Rac1 and RhoA
(Fig. 6d). The quanti!cation of these immunohistochemical
experiments is shown in Supplementary Fig. 5b.
The immunoreactive signals obtained with each of those
antibodies always display much higher intensities in the Vav2Onc
samples that in controls, indicating that they are not merely the
consequence of the expansion of proliferative cell layers that
already contain very high levels of activation of these transcrip-
tional factors. Consistent with this, we also observed that the
immunoreactivity of c-Fos, c-Myc, and YAP is detected in upper
cell layers of the organotypic cultures that are negative for the
proliferative markers Cyclin D1 (Fig. 6c) and Ki67 (Fig. 4c). To
further con!rm that the stimulation of these factors is the result
of the direct downstream signaling of Vav2Onc, we investigated
whether the transient expression of the active version of this GEF
could promote the stimulation of these transcriptional factors
using luciferase reporter assays in 2D keratinocyte cultures. In
agreement with the organotypic data, we found that the transient
expression of Vav2Onc leads to the stimulation of the transcrip-
tional activity of the endogenous AP1 factors (Fig. 6e), c-MYC
(Fig. 6f), E2F proteins (Fig. 6g), and the YAP/TAZ/TEAD
complex (Fig. 6h). These effects are severely reduced when using
the catalytically dead Vav2Onc+E200A protein (Fig. 6e to h).
Immunoblot analyses con!rmed the proper expression of the
ectopically expressed proteins used in these experiments (Fig. 6i).
These data indicate that Vav2Onc stimulates all these transcrip-
tional factors in a catalysis-dependent and signaling autonomous-
manner.
Further linking Vav2 with the stimulation of these factors, we
observed using in silico analyses that the expression of well-
known c-MYC- (Fig. 6j) and YAP/TAZ/TEAD-regulated (Fig. 6k)
gene signatures is directly proportional to the abundance of the
VAV2 transcripts in both human cSCC and HPV– hnSCC patient
samples. The correlation between VAV2 transcript levels and the
c-MYC- (Fig. 6j, bottom right panel) and YAP/TAZ-regulated
(Fig. 6k, bottom right panel) gene signatures is lost in most cases
when the hnSCC samples are not strati!ed according to HPV
status, further linking this Vav2Onc-driven pathobiological
program to HPV– tumor cases.
The hyperplasia induced by Vav2 is c-MYC- and YAP-
dependent. Given the above results, we next investigated the
potential implication of c-MYC and YAP/TAZ in the hyperplasia
triggered by Vav2Onc and Rac1F28L+ RhoAF30L using a phar-
macological approach. To this end, we chose concentrations of
inhibitors of c-MYC (10058-F4) and YAP (Vertepor!n) that did
not cause signi!cant interference with the growth and differ-
entiation of control cells in the 3D cultures (Fig. 7a, top panels;
Fig. 7b). With this strategy, we expected to unveil vulnerabilities
speci!cally associated with the gain-of-function events elicited by
the VAV2–GTPase signaling axis in these cells. We found that the
inhibition of c-MYC blocks the epidermal hyperplasia induced by
Vav2Onc- and Rac1F28L+ RhoAF30L-expressing keratinocytes
(Fig. 7a, compare left and middle columns of panels; Fig. 7b).
This effect is similar to that elicited by the incubation of these
organotypic cultures with Pak and Rock inhibitors (see above,
Supplementary Fig. 3e, f). We did not !nd any histological signs
of cell differentiation (Fig. 7a), suggesting that the inhibition of
c-MYC preferentially impacts on the proliferation of those cells.
As a result, the epidermis formed by Vav2Onc- and Rac1F28L+
RhoAF30L-expressing keratinocytes under those conditions clo-
sely resemble those generated by the control, mock-transduced
cells (Fig. 7a, b). The addition of the YAP inhibitor does not block
the hyperplasia exhibited by Vav2Onc-expressing cells. However,
it does prompt the differentiation of all the immature keratino-
cyte cell layers but the most basal one (Fig. 7a, compare !rst and
third columns of panels from left; Fig. 7b). This indicates that the
YAP/TAZ/TEAD complex is mainly involved in sustaining the
undifferentiated phenotype of suprabasal cell layers. To demon-
strate the inhibition of the expected targets by the foregoing
inhibitors, we evaluated c-MYC and YAP/TAZ/TEAD tran-
scriptional activity in human keratinocyte 2D cultures transiently
transfected with the indicated Vav2Onc versions plus luciferase
reporter plasmids containing either c-MYC- or TEAD-responsive
promoters, respectively. We observed that the addition of 10058-
F4 blocks both the basal and the Vav2Onc-driven MYC activity in
those cells (Fig. 7c, left panel). On the other hand, Verterpor!n
reduces the basal and the Vav2Onc-triggered transcriptional
activity of TEAD in these culture conditions (Fig. 7c, right panel).
It has been previously shown that the activation and inactivation
of the YAP/TAZ/TEAD promotes and blocks epithelial hyper-
plasia, respectively3–5. However, dependent on the experimental
Fig. 5 Vav2 controls a protumorigenic stem cell-like program in keratinocytes. a Main functional categories encoded by the Vav2Onc-dependent
transcriptome. For all of them, P < 0.001 (Fisher’s exact test). b Gene signatures dysregulated in the Vav2Onc-dependent transcriptome. FDR q value <
0.0001 (GSEA statistical test). NES normalized enrichment score. Negative and positive enrichments are indicated with downward and upward arrows,
respectively. c Time-course showing the changes in the thickness (left) and BrdU incorporation (right) of the epidermis of mice of the indicated genotypes
in response to topic applications of TPA. **P= 0.002 (epidermal thickness, 24 h), 0.009 (BrdU incorporation, 24 h); ***P < 0.0001 (all other tests) using
two-tailed Student’s t-test, n= 3 independent experiments). d Representative image (left panel) and quanti!cation (middle panel) of the number of
induced pluripotent stem cell (iPSC) colonies generated by keratinocytes of the indicated genotypes upon transduction with the Yamanaka’s cocktail. As a
control, the quanti!cation of the pluripotency marker Nanog in the cultures is shown (right panel). ***P < 0.0001 (two-tailed Student’s t-test, n= 3
independent experiments). e Fraction of the upregulated (top panels) and downregulated (bottom panels) Vav2Onc/Onc-driven transcriptome showing
conservation with mouse cSCC (left panels), human cSCC (middle panels), and human hnSCC (right panels) transcriptomes. The number of tumor
samples is indicated at the bottom. The level of conserved probe sets (CPS) is shown on the right of each panel. AK, actinic keratosis. f GSEA of the
indicated gene sets (top) in the Vav2Onc/Onc-regulated transcriptome. The NES and FDR values are indicated within each graph (GSEA statistical test).
Positive enrichments are indicated with upward arrows. The conversion of mouse to human probe set has been made using the hgu133plus2 platform. In
c and d, data are given as the mean ± SEM. Source data for this !gure are provided as a Source Data !le.
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setting used, c-MYC has been associated with either regenerative
proliferation or terminal differentiation in keratinocytes7. Con-
sistent with this latter mechanism of action and the data obtained
in our current work, we found that the stable ectopic expression
of c-MYC in human keratinocytes (Fig. 7d) elicits a Vav2Onc-like
phenotype in the 3D organotypic cultures (Fig. 7e). These results
indicate that c-MYC and the YAP/TAZ/TEAD complex are key
distal elements of the VAV2 pathway that promotes the acqui-
sition of SCC-like molecular features by epithelial cells.
Wild-type VAV2 triggers keratinocyte hyperplasia. Given that
the overexpression of VAV2WT is the most common event in
hnSCC, we next investigated whether the overexpression of the
***
WT Mock +Vav2OncWT
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full-length version of this protein could induce a Vav2Onc-like
phenotype in nontransformed keratinocytes. To this end, we
generated two independent pools of human keratinocytes
expressing high levels of ectopically expressed Vav2WT (Fig. 8a).
Immunoprecipitation experiments indicated that this protein is
tyrosine phosphorylated (Fig. 8b) and that it coimmunopreci-
pitates with a large molecular weight tyrosine-phosphorylated
protein in these cells (Fig. 8b, asterisk). Based on previous
results, it is likely that this protein corresponds to the autop-
hosphorylated EGFR32,33. As control, we included in these
experiments the previously described pools of human kerati-
nocytes expressing either Vav2Onc or the catalytically dead
Vav2Onc+E200A mutant protein (Fig. 8a). We observed that the
keratinocytes ectopically expressing Vav2WT generate thicker
epithelial layers than control cells when tested in organotypic
cultures (Fig. 8c, d). This phenotype, however, is milder than the
exhibited by Vav2Onc-expressing cells (Fig. 8c, d). Consistent
with previous data (Fig. 4b, d), the keratinocytes expressing
Vav2Onc+E200A generate epithelial structures similar to controls
(Fig. 8c, d). These results indicate that the overexpression of the
full-length Vav2, the version of the protein commonly found
deregulated in cSCC and hnSCCs (see above, Figs. 1 and 2,
Supplementary Fig. 1), also promotes epithelial hyperplasia
when overexpressed in human keratinocytes.
Endogenous VAV2WT is required for hnSCC maintenance.
Having proved that Vav2 activity is associated with the engage-
ment of a regenerative proliferation and a cell undifferentiation
state in normal keratinocytes, we next investigated whether
VAV2 was also important to maintain those traits in already
transformed hnSCC cells. To this end, we knocked down the
endogenous VAV2 transcripts using several independent shRNAs
in a widely-used hnSCC cell line (SSC-25)34 and in two HPV–
patient-derived cells obtained from two independent oral SCC
cases (VdH01, VdH15)35. Unlike the case of SCC-25 cells that
have been previously characterized (Supplementary Fig. 6a–c)36,
the genomic alterations present in the VdH01 and VdH15 cells
remain unknown. Due to this, we characterized the whole gen-
ome of both patient-derived cells through next generation
sequencing (Supplementary Note 1, Supplementary Fig. 6 and
Supplementary References). When tested in organotypic cultures,
we observed that all the control cells bearing an empty lentiviral
vector (referred to as “pLKO” cells) form in all cases unstructured
tumor masses composed of highly proliferative (Ki67+) and
undifferentiated (keratin 14+, involucrin–) cell layers according to
immunohistochemical staining (Fig. 9a). By contrast, the VAV2
knockdown cells (Supplementary Fig. 7) generate under the same
conditions thinner and more epithelioid structures (Fig. 9a and
Supplementary Fig. 8a) that, in some cases (e.g., VHd15 cells) can
even form a corneum stratum (Fig. 9a). However, unlike the case
of normal keratinocytes, the knockdown cells cannot enucleate
properly during the formation of this latter cell layer (Fig. 9a).
The organotypic cultures from VAV2 knockdown cells also dis-
play a reduction in Ki67+ levels and the presence of upper cell
layers composed of differentiated, involucrin+ cells (Fig. 9a and
Supplementary Fig. 8b). To analyze the behavior of the VAV2
knockdown patient-derived cells in vivo, we transplanted them
orthotopically in the tongue of Vav1–/–;Vav2–/–;Vav3–/– mice. As
these mice are lymphopenic37,38 and generated in our own animal
facility, they represent a cheap alternative to the use of the
commercial immunode!cient mouse strains typically used for this
type of experiments. Using this model, we found that the hnSCC
patient-derived cells bearing the VAV2 shRNA show reductions
in both the tumorigenic (Fig. 9b, c) and metastatic (Fig. 9d)
potential when compared to controls. Interestingly, we also
observed that the small tumors generated by the VAV2 knock-
down cells undergo a process of keratinization and differentiation
without proper enucleation similar to that found in the organo-
typic cultures (Fig. 9e). These results indicate that the elimination
of endogenous VAV2 in hnSCC cells induces an effect opposite to
that elicited by upregulated VAV2 signaling in primary, non-
transformed keratinocytes. Consistent with this, we observed that
the transcriptional activity of the endogenous c-MYC, YAP/TAZ/
TEAD, AP1, and E2F transcriptional factors is severely reduced in
the VAV2 knockdown patient-derived cells and SSC-25 cells
when compared to the respective controls (Fig. 9f). Likewise, the
3D structures generated by those cells show lower c-MYC (Sup-
plementary Fig. 8c, upper panels), YAP (Supplementary Fig. 8c,
middle panels), and c-FOS (Supplementary Fig. 8c, bottom
panels) immunoreactivity than controls. Similar results are
obtained when the expression of those three transcriptional fac-
tors is measured in tumors from the xenograft experiments
(Fig. 9g, h and Supplementary Fig. 8d). Further demonstrating
the importance of this VAV2 catalysis-dependent pathway for
Fig. 6 Transcriptional factors involved in the Vav2Onc-dependent transcriptome. a Transcription factor binding sites found enriched in the promoter
regions of up- (red) and downregulated (blue) genes present in the “redundant” fraction of the Vav2Onc-driven transcriptome. The NES and percentage of
hits for each transcription factor binding site are also indicated. b Circos plot of the differentially expressed genes in the Vav2Onc mouse skin. For each gene,
the expression heatmap, the chromosomal location (1–19, X, Y), the binding sites for the indicated transcription factors, and the mirror-image behavior in
the Vav2Onc-regulated transcriptome and the Vav2;Vav3-dependent fraction of the TPA-stimulated gene expression program in the skin of mice are
indicated. Red, redundant; Nonred, nonreduntant. c Expression of indicated proteins (left) in the epidermis of the back skin of WT and Vav2Onc/Onc mice
(left), 3D organotypic cultures from WT and Vav2Onc/Onc primary keratinocytes (middle), and 3D cultures of human keratinocytes (right). In the case of
the immuno"uorescence experiments using c-Myc antibodies (back skin, green color), sections were decorated with K14 (red color) and DAPI (blue color).
Scale bar, 10 !m (n= 3 independent analyses for each experimental group). d Expression of indicated proteins (left) in 3D cultures of control and Rac1F28L+
RhoAF30L-expressing human keratinocytes. Scale bar, 10 !m (n= 3 independent cultures). e–h Transiently transfected Vav2Onc triggers the rapid activation
of endogenous AP1 (e), c-MYC (f), E2F- (g), and TEAD (h) proteins in human keratinocytes. Activity was measured using luciferase-encoding vectors
containing promoter regions for each of the interrogated transcriptional factors, as described in Methods. Data represent the mean ± SEM. Black and gray
stars indicate the P value of the indicated experimental values when compared to EGFP- and EGFP-Vav2Onc-transfected cells, respectively. *P= 0.011
(Vav2Onc+E200A) versus Vav2Onc, TEAD); **P= 0.008 (Vav2Onc versus EGFP, AP1), 0.010 (Vav2Onc+E200A) versus Vav2Onc, AP1), 0.002 (Vav2Onc versus
EGFP, E2F); ***P < 0.0001 (all other tests) (ANOVA and Tukey’s HSD test, n= 3 independent experiments). i Expression of indicated proteins in one of the
experiments performed in e to h. Tubulin was used as loading control (bottom panel) (n= 3 independent experiments). j, k Correlation between the levels of
the VAV2 mRNA and the expression of c-MYC- (j) and YAP/TEAD-regulated- (k) gene signatures in the indicated (top) cSCC (n= 40) and hnSCC (n=
685) gene expression datasets. **P= 0.007 (VAV2 medium, MYC signature, GSE30784), 0.005 (VAV2 high, MYC signature, HPV- TCGA), 0.008 (VAV2
high, YAP signature, GSE45216), 0.002 (VAV2 medium, YAP signature, GSE30784); ***, P < 0.0001 (all other experiments) using the ANOVA and
Dunnett’s multiple comparison test). Data represent the mean ± SEM. Source data for this !gure are provided as a Source Data !le.
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Fig. 7 Vav2Onc-driven hyperplasia is c-MYC- and YAP-dependent. a Histological sections of 3D organotypic cultures of human keratinocytes expressing
the indicated proteins (left) that have been treated with the inhibitors shown on top. Scale bar, 10 !m (n= 3 independent cultures). b Thickness of the
cellular and corneum strata using data from a. *P= 0.012 (Vav2Onc vehicle, stratum corneum), 0.037 (Rac1F28L+ RhoAF30L vehicle, stratum corneum);
***P < 0.0001 (all other tests) (ANOVA and Dunnett’s multiple comparison test, n= 3 independent cultures). c Demonstration that the transcriptional
activity of c-MYC and TEAD is inhibited by MYC (10058-F4) and YAP/TEAD interaction (Vertepor!n) inhibitors, respectively. Black and gray stars
indicate the P value of the indicated experimental values when compared to EGFP-transfected and vehicle-treated cells, respectively. **P= 0.003 (EGFP,
100058-F4, MYC activity), 0.002 (Vav2Onc+E200A, 100058-F4, MYC activity), 0.001 (Vav2Onc+E200A, vehicle, YAP/TEAD activity), 0.001 (EGFP,
Vertepor!n, YAP/TEAD activity), 0.002 (Vav2Onc+E200A, Vertepor!n, YAP/TEAD activity); ***, P < 0.0001 (all other tests) (ANOVA and Tukey’s HSD
test, n= 3 independent experiments). d Expression of endogenous and ectopic c-Myc in indicated cell lines. Tubulin was used as loading control (bottom).
n= 3 independent experiments. e Staining of indicated human keratinocytes (left) with hematoxylin-eosin (left and middle two rows of panels) and
antibodies to Ki67 (two top middle panels), IVL (two right panels on top, red color), K14 (two right panels on top, green color), ectopically expressed c-Myc
(left bottom panel), endogenous Cyclin D1 (middle bottom panel) and endogenous c-FOS (right bottom panel). When indicated, some sections were
counterstained with DAPI (two right panels on top. blue color). Scale bar, 10 !m (n= 3 independent cultures). In b and c, data represent the mean ± SEM.
Source data for this !gure are provided as a Source Data !le.
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hnSCC tumorigenicity, we observed that the addition of chemical
inhibitors for RAC1 (1A116)39, c-MYC, and YAP promotes a
VAV2 knockdown-like phenotype when added to the organotypic
cultures of VdH15 cells (Supplementary Fig. 9). Together with the
conservation found for the Vav2Onc-regulated gene signatures in
hnSCC patients (Fig. 5e, f), these data indicate that endogenous
VAV2 is important to maintain the proliferation and undiffer-
entiation state of hnSCC cells.
Prognostic value of Vav2Onc-regulated gene signatures. The
foregoing data, coupled with the prognostic power exhibited by
the levels of VAV2 mRNA transcripts in hnSCC patients
(Fig. 1b), suggested that the Vav2Onc-regulated gene expression
landscape could be used to develop better prognostic tools for this
tumor type. Concurring with this hypothesis, we found using
bioinformatics techniques that the levels of expression of the
whole Vav2Onc-dependent transcriptome (Supplementary
Data 1) correlate with poor HPV– hnSCC patient prognosis
(Fig. 10a). This was observed in the three independent datasets
that were chosen for the in silico studies (GSE41613 [P= 0.0092,
Fig. 10a], TCGA [P= 0.0068], and GSE42743 [P= 0.0361]).
Based on these observations, we aimed at identifying a minimal
gene signature that could predict long-term survival in those
patients. As a !rst step towards this direction, we developed a
!rst-generation Vav2Onc gene signature (Vav2Onc-Sig) composed
of a reduced number (187) of humanized probe sets (Fig. 10b,
dark red area; Supplementary Table 3) that ful!lled the following
a priori criteria: (i) Statistically signi!cant deregulation in the
Vav2Onc-expressing mouse epidermis when compared to the
epidermis of WT mice. (ii) Opposite pattern of regulation in the
Vav2Onc epidermis and the TPA-stimulated skin of Vav2–/–;
Vav3–/– animals (Supplementary Fig. 4, Fig. 10b, and Supple-
mentary Table 2; to make sure that they were regulated by the
endogenous Vav2 proteins in a fully signaling autonomous
manner). (iii) Similar patterns of deregulation when using human
tumors versus healthy tissue samples (Figs. 5e, f and 10b; to make
sure that such a deregulation was conserved across species). In
good agreement with its association with the VAV2 pathway, the
levels of expression of the Vav2Onc-Sig correlated well with the
abundance of VAV2 transcripts in HPV– hnSCC samples
(Fig. 10c). We also demonstrated using principal component
analyses that the expression of the Vav2Onc-Sig in those tumors is
not indirectly caused by programs commonly found in most
tumorigenic processes9,40. Hence, this signature shows a speci!c
enrichment in human cSCC, hnSCC, actinic keratosis cases
(Fig. 10d, area shaded in light red) and a very limited number of
non-small cell lung tumors (Fig. 10d, blue dots). By contrast, it is




























































































































Fig. 8 Wild-type VAV2 also triggers keratinocyte hyperplasia. a Immunoblots showing the expression of the indicated Vav2 proteins in human
keratinocytes (top panel). Tubulin was used as loading control in all cases (bottom panel) (n= 3 independent experiments). p1 and p2 refer to two
independent pools of cells. b Tyrosine-phosphorylation levels (top panel) of immunoprecipitated Vav2WT (bottom panel) in the keratinocyte cell lines.
Similar data were obtained in two additional independent experiments. p, tyrosine-phosphorylated. IgG, immunoglobulin band derived from the antibody
used in the immunoprecipitation step. The asterisk marks a high molecular weight tyrosine-phosphorylated protein that coimmunoprecipitates with Vav2.
c Representative images of hematoxylin/eosin-stained organotypic cultures generated by the indicated cells (top). The thickness of the corneum and
cellular epidermal strata is indicated with red and blue brackets, respectively. Scale bar, 10 !m (n= 3 independent cultures). d Thickness of the cellular and
corneum strata using data from c. *P= 0.013; ***P < 0.0001 (ANOVA and Dunnett’s multiple comparison test, n= 3 independent cultures). Data represent
the mean ± SEM. Source data for this !gure are provided as a Source Data !le.
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Fig. 9 Endogenous VAV2 is required for the !tness of hnSCC cells. a Images of sections from organotypic cultures of the indicated control (pLKO) and
VAV2 knockdown (shVAV2) cell lines upon staining with hematoxylin-eosin (two left columns of panels) and antibodies to Ki67 (two middle columns of
panels), IVL and K14 (two right columns of panels). Some of the sections were counterstained with either hematoxylin (two middle columns of panels) or
DAPI (two right columns of panels, blue color). The speci!c cell line and experimental modi!cation used is shown on the left and top, respectively. pLKO,
cells transduced with an empty lentivirus. shVAV2#3, cells transduced with a lentivirus encoding the VAV2 shRNA #3. The same notation will be used
in the rest of panels of this !gure. Scale bar, 10 !m (n= 5 independent cultures). b Luminescence readings at the endpoint of the tongue orthotopic
xenograft experiment using the indicated VdH15 cells (n= 8 per cell type derivative). pt, primary tumor; m, metastasis. c Photon "ux of the indicated
xenografted animals according to data from panel b. Data represent the mean ± SEM. *P= 0.010 and 0.012, respectively (day 7); ***P < 0.0001 (day 14)
(Kruskal–Wallis test, n= 8). d Lymph node metastatic events detected in animals used in panel b. Data represent percentage. ***P < 0.0001 (Chi-squared
test, n= 8). e Histological sections of the SCC tumors formed by the indicated VdH15 cells in the experiments shown in b. Scale bar, 75 !m (n= 8 per cell
type derivative). f Luciferase activity recorded in the indicated cells (left) upon transient transfection with plasmids encoding the luciferase gene under the
regulation of promoters regulated by the indicated transcriptional factors (top). For each condition, the mean and the SEM are indicated in black and gray,
respectively. The color gradient is proportional to the level of inhibition achieved when compared to control cells (whose values are shown in red). #1,
#2 and #3 (left) refer to the independent shRNAs used to knockdown endogenous VAV2. For all of them, P < 0.001 (ANOVA and Dunnett’s multiple
comparison test, n= 3 independent experiments). g Expression of indicated proteins (top) in tumors formed in the experiment shown in b. Scale bar,
50 !m (n= 8). h Quanti!cation of immunohistochemical data from g. **P= 0.001; ***P < 0.0001 (two-tailed Student’s t-test, n= 8). Data represent the
mean ± SEM. Source data for this !gure are provided as a Source Data !le.
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light brown), the large majority of non-small cell lung cancer
patient samples (Fig. 10d, area shaded in light blue), and unre-
lated tumors such as T cell acute lymphoblastic leukemia
(Fig. 10d, area shaded in light green). When tested prognostically
using the GSE41613 gene expression dataset, we observed that the
Vav2Onc-Sig can stratify HPV– hnSCC patients according to
long-term survival criteria with better resolution (Fig. 10e, P=
2.4 ! 10–4) than the abundance of the VAV2 mRNA (Fig. 1b, P=
0.0079) and the overall Vav2Onc-regulated transcriptome
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Fig. 10 A prognostic Vav2Onc-regulated gene signature for HPV– hnSCC. a Survival of HPV! hnSCC patients (n= 97) according to the expression of the
raw Vav2Onc-driven transcriptome. The Mantel–Cox test P value is indicated. b Venn diagram representing the criteria used to select the Vav2Onc-Sig (dark
red color). The datasets used include: the Vav2Onc-driven transcriptome (Vav2Onc skin), the Vav2–/–;Vav3–/–-dependent fraction of the transcriptome
induced by TPA (12-O-tetradecanoyl-phorbol-13-acetate) in the mouse skin (Vav2–/–;Vav3–/–+TPA skin), and the human cSCC- and hnSCC-associated
transcriptomes. c Correlation between VAV2 mRNA levels and the enrichment of the Vav2Onc-Sig in the indicated gene expression datasets (top). The
P value of the F-test assessing the signi!cance of the non-zero slope is indicated. d Principal component analysis showing the enrichment of the Vav2Onc-
Sig across the indicated tumor-associated transcriptomes. NSCLC, non-small cell lung cancer; T-ALL, T-cell acute lymphoblastic leukemia. e Survival of
HPV– hnSCC (n= 97) patients according to the levels of the Vav2Onc-Sig present in tumors. The Mantel–Cox test P values obtained in each analysis are
indicated. f Survival of hnSCC patients according to levels of the MVGS (minimal Vav2Onc gene signature) using the indicated datasets (top). The
Mantel–Cox test P values obtained in each analysis are indicated. In a, c, e, and f, the datasets used for the in silico analyses are shown on top of each
graph. Source data for this !gure are provided as a Source Data !le.
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of HPV– hnSCC patients of the TCGA (P= 0.0068) and the
GSE42743 (P= 0.036) datasets. Based on this information, we next
generated a second-generation, minimal Vav2Onc gene signature
(MVGS) from the Vav2Onc-Sig using the Cox proportional-hazards
regression model. This MVGS, which only contains 47 probe sets
(corresponding to 41 independent Vav2Onc-regulated genes, Sup-
plementary Table 4), has even better prognostic power than the
foregoing gene signatures to predict the long-term survival of the
HPV– patients contained in the GSE41613 (Fig. 10f, left panel), the
TCGA (Fig. 10f, second panel from left) and in the GSE42743
(Fig. 10f, third panel from left) datasets. In this case, that signature
could also stratify the whole cohort of TCGA patients that were not
subclassi!ed according to HPV status (Fig. 10f, right panel).
However, the differences in the median survival time between the
high- and low-risk groups is much smaller in this latter case than
in the HPV– patient cohorts (Fig. 10f, compare the right panel
with the rest of graphs). This result further indicates that the
VAV2-dependent pathobiological program reported here is mainly
involved in HPV– tumor malignancy.
Discussion
Clinical and Pan-Cancer data support the idea that stem cell-like
regenerative proliferation and delays in cell differentiation con-
tribute to the malignancy of SCCs and, possibly, other cancer
types1,41–44. These traits can be elicited by the expansion of
cancer stem cell populations within tumors and/or through the
dedifferentiation of cancer cells. This process can be even more
plastic in the case of cSCC and hnSCC due to intrinsic biological
properties of the cell types that originate those tumors. For
example, it is currently known that bidirectional transitions exist
between hair follicle stem cells and more differentiated epithelial
cells as well as between basal and suprabasal keratinocytes under
speci!c physiological conditions45,46. Unfortunately, we still have
a shallow understanding of the molecular and signaling events
underpinning the emergence of these malignant traits and, as a
consequence, on how to effectively deal with them at the ther-
apeutic level. In this work, we have shown that the RHO GEF
VAV2 is a common driver for these processes in keratinocytes
from different anatomical locations. Consistent with this, we
have demonstrated that the upregulation of VAV2 catalytic
activity promotes the development of a hyperplasic phenotype
that, when combined with additional genetic lesions, facilitates
tumor development and progression. Perhaps more importantly,
we have observed that endogenous VAV2 is required for the
maintenance of those malignant traits in both HPV– hnSCC
patient-derived cells and established hnSCC cell lines. These
effects are associated with the stimulation of a number of tran-
scriptional factors (AP1, c-MYC, E2F, NFY, TEAD) that coor-
dinately work in the orchestration of gene expression changes
linked to both stem cell-like regenerative proliferation and delays
in cell differentiation in this type of tumors1,2,43,44,47,48. Our gain-
and loss-of-function experiments have validated the functional
correlation of VAV2 activity with the expression of these tran-
scriptional factors in both hyperplasic epithelia and patient-
derived cells. They also demonstrated that their stimulation is a
direct downstream effect of Vav2Onc catalysis-dependent signal-
ing. These !ndings, together with recent observations indicating
that the depletion of RAC1 restores chemo and radiosensitivity to
hnSCC cell lines12, suggest that the inhibition of the enzyme
activity of this GEF could be a potential therapeutic avenue in a
signi!cant percentage of SCCs. In agreement with this possibility,
we have recently shown using a Vav2 knock-in mouse strain that
the expression of a catalytic hypomorphic Vav2 mutant (L332A)
impairs the development of DMBA- and DMBA plus TPA-
induced skin tumors18.
Further supporting its contribution to both cSCC and hnSCC
tumorigenesis, we have observed that the abundance of both
VAV2 and the VAV2 transcripts becomes exacerbated in some of
these tumors. The levels of VAV2 transcripts and Vav2Onc-driven
gene signatures also correlate with the poor prognosis of HPV–
hnSCC patients. These results indicate that approximately 30% of
cancer patients could be strati!ed differently based on these
molecular features. This proportion is comparable to, and even
higher than those found for patients bearing genetic alterations in
bona-!de hnSCC drivers such as the EGFR, KRAS, ACTL6A, and
c-MYC1,2. However, unlike those cases, the deregulation of the
VAV2 pathway is not associated with locus-speci!c genetic
alterations. The molecular basis for the aberrant upregulation of
VAV2 in these tumors remains to be addressed. Possible expla-
nations include the ampli!cation of super-enhancers and the
spurious activation of transcriptional factors49. It is also possible
that processes associated with increased mRNA translation could
contribute to the upregulation of VAV2 signaling. This possibility
is consistent with the presence in the 3' untranslated region of the
VAV2 mRNA of two cytoplasmic polyadenylation elements
usually associated with increased translational ef!ciencies50.
Finally, it can be the product of a positive feed-back mechanism
in which the normal expression of VAV2 seen in normal basal
epithelial cells is further ampli!ed as they progress along the
transformation process. In any case, this dysregulation seems to
be rather speci!c since the expression of genes located in the
vicinity of VAV2 do not exhibit any kind of dysregulation in the
tumor expression datasets analyzed in this work. VAV2 is seldom
mutated in hnSCCs according to cBioPortal-archived cancer
genome data24–26, indicating that the overexpression of the WT
protein will be the most relevant type of deregulation found for
this pathway in this tumor type. Consistent with this, we have
found that human keratinocytes ectopically expressing Vav2WT
can also generate a hyperplasic epithelium when tested in orga-
notypic cultures. Conversely, the elimination of the highly
expressed endogenous VAV2 protein negatively affects the
transforming potential of HPV– hnSCC patient-derived cells. It is
worth noting, however, that a recent study has found a recurrent
gain-of-function mutation for VAV2 in cases of familial oral
SCC27. The results obtained with the Vav2Onc/Onc mouse strain
in the present study suggest that this gain-of-function VAV2
mutation, in combination with other genetic alterations, should
contribute to the etiology of this type of hereditary cancers. In
addition, they provide a pathobiological framework to understand
the contribution of mutant VAV2 to this rare hereditary cancer.
Although cSCC and hnSCC share many molecular and
pathobiological features with other SCCs1,2,9,40,51, we have not
found any overt deregulation of VAV2 expression in SCCs from
other locations. Likewise, the Vav2Onc-driven diagnostic gene
signatures described in this work are only conserved in a very
small subset of non-small cell lung cancer patients (Fig. 10d). The
reason for such a speci!city can be several-fold. It might represent
a mechanism to optimally stimulate the YAP/TAZ/TEAD com-
plex, given that the activation of this transcriptomal complex
takes place in a Hippo-independent manner in this type of epi-
thelia3. Alternatively, it might constitute an adaptive solution to
promote the chronic, RAC1-dependent activation of JNK that
could contribute to overcome the terminal differentiation-based
tumor suppressor mechanism that speci!cally operates in these
cells52,53. Supporting this view, the expression of Vav2Onc does
not elicit the terminal differentiation in epithelial cells that has
been found before upon the expression of oncogenic versions of
phosphatidylinositol 3-kinase "52. However, it is also possible that
other SCCs could utilize redundant pathobiological programs that
make it unnecessary the upregulation of VAV2 signaling. Further
work will be needed to address these possibilities.
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The full understanding of the role of RHO GEFs and GTPases
in cancer has been historically hijacked by a cell biology-centered
vision on their roles in cytoskeletal regulation. However, recent
data gathered from animal models, genome-wide expression
analyses, and Pan-Cancer projects are beginning to illuminate
new, and in some cases quite unsuspected roles for these proteins
in both tumor promotion and suppression10,54. This integrative
approach has been instrumental to identify the VAV2-dependent
program reported here. Our in silico analyses of gene expression
data also have revealed that, in addition to VAV2, four additional
RHO GEFs can probably play protumorigenic functions in both
cSCC and hnSCC. It will be interesting to investigate in the near
future the speci!c roles of these additional RHO GEF family
members in these tumors. Given the results obtained with the
single inactivation of VAV2, we postulate that these additional
GEFs will play nonredundant functions in these tumors. The
experimental approach used here can be also utilized to pinpoint
therapeutically interesting RHO signaling elements in any tumor
type with a more rational and patient-oriented aprioristic basis.
Methods
Ethics statement. Animal work was done according to protocols approved by the
Bioethics committee of Salamanca University. The use of patient samples was
conducted in accordance to the Declaration of Helsinki and approved by the
Institutional Ethic Committees of the Institute for Research in Biomedicine, Vall
d’Hebron Research Institute, and the Hospital Universitario Central de Asturias.
All patient samples have been collected with a priori patient consent.
Plasmids. To generate the lentiviral vector encoding HA-tagged Vav2 (pCCM33)55,
a cDNA fragment encoding mouse wild type Vav2 was ampli!ed by PCR using as
template the pCMV!Vav2-HA plasmid56. Primers were modi!ed to introduce a
SpeI site (underlined)/HA epitope (bold face) at the 5' end and a NotI site
(underlined) at the 3' end in the ampli!ed product. The sequence of the forward and
reverse primers were 5'-AAT AAC TAG TGC CAC CAT GTA CCC ATA CGA
CGT CCC AGA CTA CGC TGA GCA GTG GCG GCA ATG CGG C-3' and 5'-
ATA GAC CGC GGC CGC TCA CTG GAT GCC CTC CTC TTC TAC GTA-3',
respectively. The ampli!ed PCR cDNA fragment was digested with the indicated
enzymes and cloned into the SpeI/NotI-linearized lentiviral vector (pLVX-IRES-
Hyg, Clontech). To generate the lentiviral vector encoding HA-tagged Vav2Onc
(pCCM34)55, a cDNA fragment encoding the HA-tagged version of Vav2 (fragment
187-868) was ampli!ed by PCR using the primers 5'-AAT AAC TAG TGC CAC
CAT GTA CCC ATA CGA CGT CCC AGA CTA CGC TAA AAT GGG AAT
GAC TGA GGA CGA C-3' and 5'-ATA GAC CGC GGC CGC TCA CTG GAT
GCC CTC CTC TTC TAC GTA-3' (restriction sites underlined) and the pCMV-
Vav2-HA vector as template56. Upon digestion with SpeI and NotI, the cDNA
fragment was cloned into the linearized pLVX-IRES-Hyg vector (Clontech, Catalog
No. 632185). To generate the vector encoding HA-Vav2Onc+E200A (pFLM12), the
pCCM34 vector was subjected to site-directed mutagenesis using the primers 5'-
GAC AAG AGA AGC TGC TGC TTG TTA GCG ATT CAG GAG ACC GAG
GCC AAG TAC-3' and 5'-CAT GAA CCG GAG CCA GAG GAC TTA GCG ATT
GTT CGT CGT CGA AGA GAA CAG-3' (changes used to generate the mutated
codon are underlined). The pMIEG3, pMIEG3-Rac1F28L, pMIEG3-RhoAF30L, and
pMIEG3-Cdc42F28L plasmids have been reported before57. To generate the plasmid
encoding EGFP-Vav2Onc (pNM115), the plasmid pKES1930 was digested with
BstXI, !lled-in, and cloned into the SmaI-linearized pEGFP-C2 vector (Clontech,
Catalog No. 632481). The plasmid encoding EGFP-Vav2Onc+E200A (pFLM07) was
obtained by site-directed mutagenesis of pNM115 using the primers 5'-GAC AAG
AGA AGC TGC TGC TTG TTA GCG ATT CAG GAG ACC GAG GCC AAG
TAC-3' and 5'-CAT GAA CCG GAG CCA GAG GAC TTA GCG ATT GTT CGT
CGT CGA AGA GAA CAG-3' (the altered nucleotides used to create the E200A
mutation are underlined). Plasmids encoding c-Myc and the Yamanaka’s factors
(Oct4, Sox2, Klf4, and c-Myc) were provided by P.M. Fernández-Salguero
(Department of Biochemistry and Molecular Biology, Extremadura University,
Badajoz, Spain).
The luciferase plasmids used to assay promoter activation included: pAP1-Luc
(AP1 reporter, obtained from Stratagene), pBV-Myc-Del1-Luc (c-Myc reporter,
obtained from Addgene, Catalog No. 16601), pGL2-Chk1-WT-Luc (E2F reporter,
obtained from A.M. Zubiaga, Department of Genetics, Physical Anthropology and
Animal Physiology, University of the Basque Country, Bilbao, Spain), p8xGTIIC-
Luc (TEAD reporter, obtained from Addgene, Catalog No. 34615), and pRL-SV40
(Renilla luciferase, obtained from Promega, Catalog No. E2231). All plasmids were
DNA sequence veri!ed.
In silico analyses of gene expression data from human tumors. All the gene
expression datasets used in our study are detailed in Supplementary Table 1. The
rationale for the selection of the expression datasets used for differential expression
analyses has been described in the main text. Speci!cally, GEO datasets GSE45216
and GSE13355 (human cSCC, n= 220 samples)58,59, GSE30784 (human hnSCC,
n= 229 samples)21, GSE21264 (mouse cSCC, n= 273 samples)60 and the TCGA
hnSCC dataset (n= 573 samples)24 were used to interrogate VAV2 mRNA
expression levels (using a 0 to 1 normalization of the expression values to that end).
Other datasets included TCGA CESC (n= 319)61 and LUSC (n= 824)62, and the
GEO T-ALL dataset GSE26713 (n= 117; used in Fig. 10)63. The R (version 3.5.1)
and Perl programs were used to carry out the statistical analyses and !nal text
processing, respectively. Signal intensity values from microarray data were
obtained from CEL !les after robust multichip average (RMA). Differentially
expressed genes were identi!ed using linear models for microarray data (Limma)64.
Adjusted P values for multiple comparisons were calculated applying the
Benjamini–Hochberg correction (false discovery rate, FDR). The head and neck,
cervix and lung SCC TCGA datasets were obtained and analyzed through the
TCGAbiolinks R package65. When data were analyzed as multiple batches
(GSE45216 and GSE13355), fRMA were used to remove batch effects66.
Overall survival analyses were performed through Kaplan-Meier estimates
according to the expression level of the indicated transcripts using the GSE41613
(n= 97 samples)67, the GSE42743 (n= 103)67, and the TCGA (see above) hnSCC
datasets. The median of the expression distribution for each of those transcripts
was used to establish the low and high expression groups and, subsequently, the
Mantel-Cox test was applied to statistically validate the differences between the
survival distributions.
Determination of HPV status of human tumor samples. HPV detection was
performed using p16 immunohistochemistry, high-risk HPV DNA detection by
in situ hybridization and genotyping by GP5+/GP6+ PCR68. In the !rst case, tissue
microarrays were cut into 3 #m sections and dried on Flex IHC microscope slides
(DakoCytomation). Immunohistochemistry was then performed using an auto-
matic staining workstation (Dako Autostainer, Dako Cytomation) with the Envi-
sion system and diamino-benzidine chromogen as substrate. The primary
antibodies used were those to both p53 (clone DO-7, DAKO) and p16 (clone E6H4
(Roche MTM laboratories AG). In the second case, we performed in situ hybri-
dization with biotinylated HPV DNA probes speci!c for HPV types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68 (DakoCytomation) according to the manu-
facturer’s instructions. The results from these two techniques were always evaluated
by two independent pathologists. In the latter case, isolated DNAs from tumor
samples were subjected to GP5+/6+-PCR using an enzyme-immuno-assay readout
to detect the 14 high-risk HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and
68 subtypes. Subsequent genotyping of the infection was performed using bead-
based arrays on the Luminex platform. When GP51= 61 PCR was positive, type-
speci!c PCR for HPV16 was performed using primers located in the E7 gene68.
Immunoprecipitation experiments. Healthy mucosa, when included in the
experiments, were obtained from the same hnSCC patients (due to this, they were
assigned the same identi!cation number shown in Fig. 2a). Tumoral and healthy
tissues (Supplementary Table 5) were mechanically homogenized in RIPA buffer
(10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1% Triton X-100 (Sigma-Aldrich,
Catalog No. X100), 1 mM Na3VO4 (Sigma-Aldrich, Catalog No. S6508), 1 mM NaF
(Sigma-Aldrich, Catalog No. S7920), and a mixture of protease inhibitors
(CØmplete; Roche, Catalog No. 11836145001) using a gentleMACS dissociator
(Miltenyi Biotec, Catalog No. 130-093-235) and gentleMACS M tubes (Myltenyi
Biotec, Catalog No. 130-096-335). Extracts were precleared by centrifugation at
13,200 rpm for 10 min at 4 °C. Protein concentration in the resulting supernatants
was quanti!ed using the Bradford reactive (Bio-Rad, Catalog No. 5000006). 400 #g
of protein extracts in a !nal volume of 500 #l of RIPA buffer were incubated with
1.5 #l of a homemade antibody to Vav2 (Lab catalog No. 580-2) for 2 h at 4 °C in a
rotating wheel. Immunocomplexes were collected with 35 #l of Gammabind
G-Sepharose beads (GE Healthcare, Catalog No. GE17-0885-01) at 50% con-
centration for another 2 h at 4 °C in a rotating wheel. After three times washes
with the lysis buffer at 4 °C, the beads were resuspended in SDS-PAGE buffer,
boiled for 5 min, and transferred onto nitrocellulose !lters using the iBlot Dry
Blotting System (Thermo Fisher Scienti!c, Catalog No. IB21001). Membranes
were blocked in 5% bovine serum albumin (Sigma-Aldrich, Catalog No. A7906)
in TBS-T (25 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Tween-20 (Sigma-
Aldrich, Catalog No. P7949)) for at least 1 h and then incubated overnight at
4 °C with antibodies to Vav2 (1:1000 dilution, see above). After stripping, the
same !lters were used to carry out a second Western blot analysis using anti-
bodies to phospho-tyrosine residues (1:1000 dilution; Santa Cruz Biotechnolo-
gies, Catalog No. sc-7020). After three washes with TBS-T to eliminate the
primary antibody, the membrane was incubated with the appropriate secondary
antibody (1:5000 dilution, GE Healthcare) for 30 min at room temperature.
Immunoreacting bands were developed using a standard chemiluminescent
method (Thermo Fisher Scienti!c, Catalog No. 32106). Blots were quanti!ed
using the ImageJ software (NIH, www.imagej.nih.gov).
In addition to protein quantitation, the total amount of protein present in each
tissue lysate was con!rmed by running aliquots of the total cellular extracts used in
the immunoprecipitation experiments in SDS-PAGE gels and, after transfer to
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nitrocellulose !lters as above, staining with Ponceau S solution (Sigma-Aldrich,
Catalog No. P7170).
In the case of keratinocyte cultures, exponentially growing cells were washed in
a phosphate-buffered saline solution and lysed with the aid of a scrapper in 1 ml of
RIPA buffer supplemented with CØmplete. Cellular extracts were kept 5 min on ice
and subsequently centrifuged at 13,200 rpm for 10 min at 4 °C to eliminate cell
debris. After protein quantitation, lysates were incubated with 1.5 #l of the
homemade antibody to Vav2 and processed as above.
Western blotting analyses of total cell extracts. In the case of tissue extracts,
samples were transferred to RIPA buffer and mechanically homogenized using the
gentleMACS dissociator. In the case of keratinocytes maintained in culture, cells
were washed with chilled phosphate buffered saline solution and then directly lysed
in RIPA buffer at 4 °C. Extracts were precleared by centrifugation at 13,200 rpm for
10 min at 4 °C, denatured by boiling in SDS-PAGE sample buffer, separated
electrophoretically, and transferred onto nitrocellulose !lters using the iBlot Dry
Blotting System. Membranes were blocked as above and then incubated overnight
at 4 °C with appropriate antibodies to Vav2 (1:1000 dilution, homemade), GFP
(1:5,000 dilution; Covance, Catalog No. MMS-118P), the hemagglutinin (HA)
epitope (1:1,000 dilution; Cell Signaling, Catalog No. 3724), Rac1 (1:1,000 dilution;
BD Biosciences, Catalog No. 610651), RhoA (1:1,000 dilution; Cell Signaling,
Catalog No. 2117), Cdc42 (1:1,000 dilution; Santa Cruz Biotechnology, Catalog No.
sc-87), c-Myc (1:1,000 dilution; Merck, Catalog No. 06-340), and tubulin " (1:2,000
dilution; Calbiochem, Catalog No. CP06). After three washes with TBS-T to
eliminate the primary antibody, immunoreacting bands were visualized as
indicated above.
Immunohistochemistry using patient samples. Surgical tissue specimens from
patients with hnSCC who underwent resection of their tumors at the Hospital
Universitario Central de Asturias between 1990 and 2010 were retrospectively
collected. The formalin-!xed, paraf!n-embedded tissues were cut into 3 µm sec-
tions and dried on Flex IHC microscope slides (Agilent, Catalog No. K8020). The
sections were deparaf!nized with standard xylene and hydrated through graded
alcohols into water. Antigen retrieval was performed using Envision Flex Target
Retrieval solution, high pH (Dako Omnis, Catalog No. GV804). Staining was done
at room temperature on an automatic staining workstation (Dako Omnis, Catalog
No. Autostainer Plus) with rabbit monoclonal antibody to VAV2 (Abcam, Catalog
No. ab52640; 1:50 dilution). Hematoxylin was used for counterstaining. The slides
were randomly analyzed and signals scored as negative (0), weak-to-moderate (1)
or strong (2). 96.55% of all the tumor samples used in these analyses were HPV!.
Mouse experiments. Vav2Onc/Onc and Vav1–/–;Vav2–/–;Vav3–/– mice have been
described elsewhere17,29. Animals were kept in ventilated rooms in pathogen-free
facilities under controlled temperature (23 °C), humidity (50%), and illumination
(12-h-light/12-h-dark cycle) conditions. For carcinogenesis experiments in new-
born mice, 3-day-old mice received a single application of 5 µg of DMBA (Sigma-
Aldrich, Catalog No. D3254) in 200 µl of acetone. The number, size, and incidence
of tumors were monitored weekly. Time-course studies of the in vivo response of
the epithelia of WT and Vav2Onc/Onc mice to TPA using both determination of
epithelial hyperplasia and BrdU incorporation were carried out as indicated
before17. Upon euthanasia, tumors and tissue samples were collected and processed
for both histological and immunohistochemical analyses.
For the orthotopic xenograft experiments, exponentially growing hnSCC
patient-derived cells were detached using Accutase (CELLnTEC, Catalog No. CnT-
Accutase-100), centrifuged at 300 ! g for 5 min, and resuspended in culture
medium at a density of 1.7 ! 106 cells per ml. 5 ! 104 SCC cells were then
introduced orthotopically using an ultra!ne 8 mm-needle (BD, Catalog No.
320927) in the tongue of 6- to 8-week-old Vav1–/–;Vav2–/–;Vav3–/– mice previously
anesthetized by injecting intraperitoneally 200 µl of a mixture of 10 mg/ml
ketamine (Merial, Catalog No. Imalgene 1000) and 2 mg/ml xylazine (Bayer,
Catalog No. Rompun) in phosphate buffered saline. Growth of tumors was then
periodically visualized using an IVIS Lumina In Vivo Imaging System
(PerkinElmer, Catalog No. CLS136334) upon administering 50 µl of a 5 mg/ml
solution of D-luciferine (Goldbio, Catalog No. LUCK-500) to mice. This procedure
was performed with animals anesthetized as above. Mice were reanimated after
!nishing the recordings by injecting intraperitoneally 200 µl of a 1 mg/ml
atipamezole (Ecuphar, Catalog No. Antisedan) solution in phosphate buffered
saline solution. Upon euthanasia, tumors were collected and processed for
pathological and immunohistochemical analyses.
When needed, tissues were extracted, !xed in 4% paraformaldehyde, paraf!n
embedded, cut in 2–3 µm thick sections, and stained with hematoxylin-eosin. The
thickness of the epidermal layer and/or total skin thickness were measured in
vertical cross-sections using the software ImageJ. In the case of tumor sections, they
were analyzed blindly by a pathologist to classify them according to malignancy
grade and level of differentiation.
Immunohistochemical studies in mice. Immunohistochemical staining was per-
formed using a Ventana Discovery Ultra instrument (Roche, Catalog No.
05987750001). Paraf!n-embedded sections were dewaxed, subjected to either
citrate buffer [pH 6.0] or Tris EDTA [pH 8.0] for heat-induced antigen retrieval,
and incubated for 40 min with the appropriate primary antibody to c-Fos (1:50
dilution, Santa Cruz Biotechnology, Catalog No. sc-166940), c-Myc (1:50 dilution,
Abcam, Catalog No. ab32072), YAP (1:200 dilution, Novus Biologicals, Catalog No.
NB110-58358), Cyclin D1 (1:200 dilution, Roche, Catalog No. 790-4508), keratin
14 (1:300 dilution, Biolegend, Catalog No. 905301), or involucrin (1:100 dilution,
Sigma-Aldrich, Catalog No. I9018). For standard staining, the Discovery OmniMap
anti-Rb HRP detection system (Roche, Catalog No. 760-4311) was used for
detection and hematoxylin for counterstaining as indicated by the manufacturer.
Quantitation of immunohistochemical signals were done using the ImageJ software
by adjusting the signal threshold to the staining intensity and measuring the area of
the resulting particles.
Cells. Primary keratinocytes were isolated as described elsewhere17. Brie"y, the
skin from newborn mice of the indicated genotypes was treated with 250 U/ml of
dispase (Roche, Catalog No. 04942078001) overnight at 4 °C. Next day, the epi-
dermis was separated from the dermis and treated with Acutase for 30 min at 37 °C
to extract the keratinocytes. Cultures were maintained in CnT07 medium
(CELLnTEC, Catalog No. CnT-07) on type I collagen-precoated plates (BD Bios-
ciences, Catalog No. 356400).
Immortalized, primary neonatal human keratinocytes (KerCT cells) were
purchased from the American Type Culture Collection (Catalog No. CRL-4048)
and cultured in KGM-Gold medium (Lonza, Catalog No. 00192060). These cells
have been immortalized by ectopically expressing human TERT and CDK4. SCC-
25 cells were obtained from S.A.B. and cultured in KSFM medium (Thermo Fisher
Scienti!c, Catalog No. 17005-042) supplemented with 25 µg/ml bovine pituitary
extract (Thermo Fisher Scienti!c, Catalog No. 17005-042) and 0.5 ng/ml human
epidermal growth factor (Thermo Fisher Scienti!c, Catalog No. 17005-042).
hnSCC (tongue-located) patient-derived cells were described elsewhere35.
VdH15 cells were cultured in KSFM medium supplemented with 25 µg/ml bovine
pituitary extract and 0.5 ng/ml human epidermal growth factor (Thermo Fisher
Scienti!c, Catalog No. 17005-042). VdH01 cells were cultured in a FAD+ medium
that was composed of three parts of DMEM (Gibco, Catalog No. 21969) and one
part of Ham’s F12 medium (Thermo Fisher Scienti!c, Catalog No.11765054)
supplemented with 10% fetal bovine serum (Gibco, Catalog No. 10270106), 1.8 !
10–4 M adenine (Sigma-Aldrich, Catalog No. A2786-5G), 0.5 µg/ml hydrocortisone
(Sigma-Aldrich, Catalog No. H4001-1G), 5 µg/ml insulin (Thermo Fisher
Scienti!c, Catalog No. 12585014), 10 ng/ml epidermal growth factor (PreproTech,
Catalog No. AF-100-15), 10–10 M cholera toxin (Sigma-Aldrich, Catalog No.
C8052-5MG), and 2 mM L-glutamine (Gibco, Catalog No. 25030024).
Three-dimensional organotypic cultures. Exponentially growing keratinocytes
maintained in CnT-Prime medium were detached using Accutase, centrifuged at
300 ! g for 5 min at room temperature, and counted. 2 ! 105 cells were seeded onto
polycarbonate inserts (Thermo Fisher Scienti!c, Catalog No. 140620) and cultured
for 2 days in CnT-Prime medium. Upon con"uency, the medium was changed to
3D-Barrier (CellnTec, Catalog No. CnT-PR-3D) and the air-lift was performed
according to the manufacturer’s instructions. 3D cultures were maintained for
12 days with three medium changes per week and !nally processed for histological
study as indicated above. When indicated, the inhibitors and corresponding
vehicles were applied in the sixth day after carrying out the airlift and refreshed
with the medium changes indicated above. Inhibitors used included FRAX597
(5 nM; Selleckchem, Catalog No. S7271), Y-27632 2HCl (1 µM; Selleckchem,
Catalog No. S1049), 1A116 (500 nM)39, 10058-F4 (500 nM; Selleckchem, Catalog
No. S7153), and vertepor!n (200 nM; Selleckchem, Catalog No. S1786). Con-
centrations of inhibitors were selected based on the induction of minor effect in the
organotypic structures formed by control cells.
Lentiviral-mediated expression of proteins in keratinocytes. For the generation
of stable cell clones, lentiviral particles were produced in HEK293T cells cultured in
DMEM (supplemented with 10% fetal bovine serum and 2mM L-glutamine) and
subsequently concentrated using the LentiX concentrator kit (Clontech, Catalog
No. 631232). Keratinocytes were then infected with control and protein-encoding
lentiviral particles in KGM-Gold medium in the presence of 8 µg/ml of polybrene
(Sigma-Aldrich, Catalog No. H9268) and selected by either antibiotic resistance or
EGFP expression by "ow cytometry. In the latter case, we used a FACSAria III "ow
cytometer (BD Biosciences) for cell puri!cation. Transduced cells were puromycin
selected as described elsewhere17. Proper protein expression was assessed by
Western blot.
RHO GTPase activation assays. Total cellular lysates were obtained as above,
snap frozen, thawed, quanti!ed for total protein concentration, and analyzed using
the Rac1, RhoA and Cdc42 G-LISA assay kits according to the manufacturer’s
instructions (Cytoskeleton, Catalog No. BK135).
Microarray experiments. Total RNA from the back epidermis of 8-week-old mice
of indicated genotypes (n= 3 per genotype) was isolated using the RNAeasy
Mini Kit (Qiagen, Catalog No. 74104) and analyzed using Affymetrix platform
(GeneChip Mouse Gene 1.0 ST arrays) as previously described by us17,55,69.
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In silico analyses of mouse expression microarray data. Initial data processing
was carried out as indicated for the human data (see above). Gene Ontology and
KEGG pathways enrichment analyses were performed using DAVID and ToppFun.
GSEA was performed using gene set permutations (n= 1000) for the assessment of
signi!cance and signal-to-noise metric for ranking genes. The gene sets used
included signatures related to: epidermal differentiation (GSE52954)70; cSCC stem
cells (GSE29328)71; embryonic stem cells (GSE10423)72; cSCC cells (GSE5576)73;
and metastatic hnSCC cells (GSE72939)35. We also used lists for transcriptional
targets for AP174, c-MYC75, E2F (signature #M40 from the Molecular Signatures
Database, Broad Institute), NFY (signature #C3:TFAC:0178 from the Molecular
Signatures Database, Broad Institute), YAP/TAZ/TEAD (GSE66083)5, and FOXO
(signature #C3:TFAC:0256 from the Molecular Signatures Database, Broad Insti-
tute). To evaluate the similarity between the transcriptional programs activated by
Vav2Onc and those differentially regulated in the indicated SCC and clinical con-
ditions, the datasets GSE45216 and GSE13355 (human cSCC), GSE30784 (human
hnSCC), and GSE21264 (mouse cSCC) were used as indicated above. To assess
conservation of the Vav2Onc transcriptional signature across tumors, a 1.5-fold
change threshold was used. Heatmaps were generated using the heatmap3 package.
To evaluate the enrichment of the Vav2Onc gene signature across SCC tumors,
ssGSEA were used.
For the discovery of transcription factor binding motifs in the promoters of
the coregulated genes, the iRegulon software was used47. A collection of 9713
position weight matrices (PWMs) was applied to analyze 10 kb-long DNA
sequences that were centered around the transcriptional start sites. Using as
criteria a maximum false discovery rate (FDR) on motif similarity below 0.001,
we performed motif detection, track discovery, motif-to-factor mapping, and
target detection. Circos plots were generated using the OmicCircos package
implemented with mouse genomic data from the UCSC Genome Browser
(https://genome.ucsc.edu), gene ontology annotation from the Gene Ontology
Consortium (http://www.geneontology.org), and transcription factor annotation
from the iRegulon tool.
To evaluate the correlation of c-MYC or YAP gene signature with VAV2mRNA
levels in tumors, we strati!ed patients according to VAV2 expression levels (low,
medium, and high, established by quantiles) and calculated the ssGSEA enrichment
score for the aforementioned signatures.
Generation of induced pluripotent stem cells. Retroviral particles encoding the
Yamanaka’s factors were used to infect primary keratinocytes obtained from
neonate mice in the presence of polybrene (8 µg/ml) and, after 2 days, transferred
to an iPSC medium composed of DMEM-GlutaMAX (Thermo Fisher Scienti!c,
Catalog No. 31966-021), 15% knockout serum replacement (Thermo Fisher Sci-
enti!c, Catalog No. 10828-028), 1x nonessential amino acids (Thermo Fisher
Scienti!c, Catalog No. 11140-035), 100 µM 2-mercapthoethanol (Thermo Fisher
Scienti!c, Catalog No. 31350-010), and 1 ! 103 u/ml LIF (Millipore, Catalog No.
ESG1107). Three days later, cells were collected using Acutase and seeded on feeder
cell layers generated as described elsewhere76. iPS cell colonies were allowed to
grow for two weeks, with daily medium changes, and !nally stained with an
alkaline phosphatase assay kit (Sigma-Aldrich, Catalog No. AB0300) according to
the manufacturer’s instructions. The generation of bona-!de iPS cells was further
con!rmed using qRT-PCR analysis to detect Nanog expression.
Analysis of mRNA abundance. Total RNA was extracted using NZYol (NZYtech,
Catalog No. MB18501) and quantitative RT-PCR performed using the Power SYBR
Green RNA-to-CT 1-Step Kit (Applied Biosystems, Catalog No. 4389986) and the
StepOnePlus Real-Time PCR System (Applied BioSystems, Catalog No. 4376600).
Raw data were analyzed using the StepOne software (Applied Biosystems). We
used the abundance of the endogenous GAPDH mRNA as internal normalization
control. Primers used for transcript quantitation included: 5!-GAC GGG GAA
CTG AAA GTC CG-3! (forward, VAV2), 5!-TTT TCC CGT GAG ACT TCT TGA
C-3! (reverse, VAV2), 5!-ATG GCC TTC CGT GTC CCC ACT G-3! (forward,
GAPDH), 5!-TGA GTG TGG CAG GGA CTC CCC A-3! (reverse, GAPDH),
5!-AAG TAC CTC AGC CTC CAG CA-3! (forward, Nanog), 5!-GTG CTG AGC
CCT TCT GAA TC-3! (reverse, Nanog), 5!-TGC ACC ACC AAC TGC TTA GC-3!
(forward, Gapdh), 5!-TCT TCT GGG TGG CAG TGA TG-3! (reverse, Gapdh).
Promoter activation assays. We utilized luciferase reporter plasmids to evaluate
the activation status of the interrogated transcriptional factors of our study. To this
end, exponentially growing human keratinocytes were transiently transfected with
40 ng of the pRL-SV40 vector encoding the Renilla luciferase for intersample
normalization, 2 µg of the appropriate EGFP and EGFP-Vav2 encoding vector, and
2 µg of the appropriate !re"y reporter plasmids containing the !re"y luciferase
gene under the regulation of AP1- (pAP1-Luc), c-Myc- (pBV-Myc-Del1-Luc), E2F-
(pGL2-Chk1-WT-Luc), and TEAD- (p8xGTIIC-Luc) responsive promoters. After
24 h, cells were lysed with Passive Lysis Buffer (Promega, Cat No. E1960) and
luciferase activities determined using the Dual Luciferase Assay System (Promega,
Cat No. E1960). In all cases, the values of !re"y luciferase activity obtained in each
experimental point were normalized taking into account the activity of the Renilla
luciferase obtained in the same samples. In addition, we analyzed aliquots of the
same lysates by Western blot to assess the appropriate expression of the ectopically
expressed proteins in each case. Values are represented in the !gures as the n-fold
change of the experimental sample relative to the activity shown by control cells
(which was given an arbitrary value of 1 in each case). When needed, these
experiments included the use of chemical inhibitors in concentrations identical to
those used in the 3D organotypic cultures.
Genomic characterization of hnSCC patient-derived cells. DNA samples from
indicated patient-derived cells were sequenced at Macrogen (Seoul, South Korea) to
a 30! depth using 150 bp paired-end reads on Illumina NovaSeq 6000. Sequenced
reads were mapped to human genome assembly GRCh37 using BWA-MEM
(v0.7.17)77 and duplicate reads were marked using Biobambam (v2.0.87)78. For
variant calling, GATK tools (v4.1.4.1)79 were used to detect substitutions and
indels. Variants per sample were called using HaplotypeCaller in GVCF mode and
a join-call cohort generated using both the CombineGVCFs, GenotypeGVCFs, and
VariantFiltration tools. Structural variants were called using the germline imple-
mentation of DELLY (v0.8.1)80. Copy number status was inferred using Canvas
(v1.40.0)81. For variant annotation, we used the Ensembl Variant Effect Predictor
(v100.2)82. Substitutions and indels were de!ned as variants with potential clinical
signi!cance when meeting the following criteria: (i) The highest allele frequency
observed for the variants in any population from 1KGP, ESP or gnomAD were less
than 0.01 or not described. (ii) The variants were predicted to have high impact on
protein function or to be deleterious based on SIFT and PolyPhen scores. Variants
reported as pathogenic by ClinVar were also selected. (iii) Variants located within
the Cancer Gene Census83. Known cancer hotspots were pinpointed using the
Cancer Hotspots database84. Copy number alterations were considered clinically
relevant if they involved oncogenic gains or tumor suppressor deletions. For
structural variants, those affecting Cancer Gene Census genes at breakpoint level
were included.
shRNA-mediated transcript knockdown. To target the VAV2 mRNA, we infected
the indicated hnSCC patient-derived and SSC-25 cells with lentiviruses encoding
either empty (TR1.5-pLKO-1-puro; Sigma-Aldrich, Catalog No. SHC001) or a
number of independent VAV2 shRNAs (TRCN0000435647, referred to in the
!gures as shRNA#1; TRCN0000436728, referred to in the !gures as shRNA#2;
TRCN0000048227, referred to in the !gures as shRNA#3; TRCN0000418821,
referred to in the !gures as shRNA#4 and TRCN0000419630, referred to in the
!gures as shRNA#5). Lentiviral vectors encoding those shRNAs were obtained
from Sigma-Aldrich. Lentiviral particle production and infections were done as
indicated above. Transduced cells were puromycin selected as described else-
where17. Proper transcript knockdown was assessed by qRT-PCR.
Development of diagnostic signatures. The criteria used to develop the Vav2Onc-
Sig have been described in the Results section. To assess its tumor speci!city, we
performed principal component analyses using the datasets indicated in the !gures.
For the development of the MVGS from the Vav2Onc-Sig, we carried out Cox
proportional-hazards regression model using the survival R package (https://cran.r-
project.org/web/views/Survival.html). Survival analyses were performed as indi-
cated above, using datasets from the GEO (GSE41613) and the TCGA (hnSCC
collection).
Statistics. The number of biological replicates (n), the type of statistical tests
performed, and the statistical signi!cance are indicated for each experiment
either in the !gure legends or in the main text. Data normality and equality of
variances were analyzed with Shapiro-Wilk and Bartlett’s tests, respectively.
Parametric distributions were analyzed using Student’s t-test (when comparing
two experimental groups) or ANOVA followed by either Dunnett’s (when
comparing more than two experimental groups with a single control group) or
Tukey’s HSD test (when comparing more than two experimental groups with
every other group). Nonparametric distributions were analyzed using either
Mann-Whitney (for comparisons of two experimental groups) or the Kruskal-
Wallis followed by Dunn’s (for comparisons of three or more than three
experimental groups) tests. The chi-squared test was used to determine the
signi!cance of the differences between expected and observed frequencies. In all
cases, values were considered signi!cant when P " 0.05. Data obtained are given
as the mean ± SEM.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
A Source Data !le is provided with this paper. The microarray data reported in this paper
has been deposited in GEO database under accession number GSE124019. In addition,
public GEO datasets GSE45216, GSE13355, GSE30784, GSE21264, GSE52651, GSE26713
and the TCGA hnSCC, CESC, and LUSC datasets have been used to interrogate VAV2
enrichment levels. Survival analyses have been performed using the GSE41613,
GSE42743, and the TCGA HNSC datasets. GSEA were performed using the datasets
GSE52954, GSE29328, GSE10423, GSE5576, GSE72939, and GSE66083. All relevant data
are available from the authors.
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